RxDoctor Payments Data

Emily Hale, NP

Family · Lillington, NCNPI 1083247308

Payments from drug & device makers

$3,472in general payments, 2019–2025

Across 182 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$786
  • Collegium Pharmaceutical, Inc.$427
  • AbbVie$309
  • Nevro Corp.$297
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$276
  • Forte Bio-pharma LLC$212
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,472 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,399
Medicare patients
150
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen184$24,765
ZtlidoLidocaine19$15,022
Xtampza ErOxycodone Myristate23$8,967
Buprenorphine36$8,703
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,189
Oxycodone Hcl123$2,631
Morphine Sulfate ErMorphine Sulfate88$2,455
Naloxone Hcl32$2,173
Pregabalin79$1,636
Gabapentin131$1,427
Diclofenac Sodium44$1,357
Cyclobenzaprine Hcl45$735
Buprenorphine Hcl15$537
Methocarbamol57$353
Morphine Sulfate21$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$786$15,02219 claims
Collegium Pharmaceutical, Inc.Xtampza Er$427$8,96723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Lillington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →